|
| 36920668 | Early Use of Biologics Reduces Healthcare Costs in Crohn's Disease: Results from a United States Population-Based Cohort. | Dig Dis Sci | 2024 |
| 38010661 | Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. | Aliment Pharmacol Ther | 2024 |
| 38069472 | Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies. | J Crohns Colitis | 2024 |
| 38008228 | Reply. | Gastroenterology | 2024 |
| 37952114 | The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. | J Crohns Colitis | 2024 |
| 37950021 | Deciphering the different phases of preclinical inflammatory bowel disease. | Nat Rev Gastroenterol Hepatol | 2024 |
| 37793031 | Lémman Index in Children: Still an Open Question. | J Crohns Colitis | 2024 |
| 37743037 | Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). | Clin Gastroenterol Hepatol | 2024 |
| 37651686 | Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. | J Crohns Colitis | 2024 |
| 37933427 | Letter: 'No first among equals'-Authors' reply. | Aliment Pharmacol Ther | 2024 |
| 38040100 | From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health. | Autoimmun Rev | 2024 |
| 37768647 | Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes. | J Crohns Colitis | 2024 |
| 37391056 | Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. | Clin Gastroenterol Hepatol | 2024 |
| 35123095 | Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes. | Clin Gastroenterol Hepatol | 2023 |
| 37951594 | Cancer Screening in Patients With Inflammatory Bowel Disease: Don't Forget the Anus! | Inflamm Bowel Dis | 2023 |
| 37506265 | Early Biologic Treatment Decreases Risk of Surgery in Crohn's Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis. | Inflamm Bowel Dis | 2023 |
| 37831398 | Do We Need AI to Diagnose AI? Diagnosis and Management of Adrenal Insufficiency Following Steroid Therapy in a Patient with Inflammatory Bowel Disease. | Dig Dis Sci | 2023 |
| 37683686 | Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. | Lancet Gastroenterol Hepatol | 2023 |
| 37645044 | Unraveling the Link between Periodontitis and Inflammatory Bowel Disease: Challenges and Outlook. | ArXiv | 2023 |
| 37574127 | Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease. | Mucosal Immunol | 2023 |
| 37499955 | Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. | Gastroenterology | 2023 |
| 37817604 | Systematic review: Scores used to predict outcomes in acute severe ulcerative colitis. | Aliment Pharmacol Ther | 2023 |
| 38029420 | HLA-DQA1*05 Not Associated With Ustekinumab Loss of Response and Antidrug Antibodies in Ulcerative Colitis and Crohn's Disease Patients. | Inflamm Bowel Dis | 2023 |
| 35676084 | Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study. | Gut | 2023 |
| 35366313 | Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. | Inflamm Bowel Dis | 2023 |
| 35522225 | Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. | Inflamm Bowel Dis | 2023 |
| 35590456 | High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course. | Inflamm Bowel Dis | 2023 |
| 37354560 | Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium. | Inflamm Bowel Dis | 2023 |
| 37322120 | Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. | Nat Med | 2023 |
| 37321356 | Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study. | Gastroenterology | 2023 |
| 37054757 | Filgotinib for the Treatment of Small Bowel Crohn's Disease: The DIVERGENCE 1 Trial. | Gastroenterology | 2023 |
| 37081213 | The appendix and ulcerative colitis - an unsolved connection. | Nat Rev Gastroenterol Hepatol | 2023 |
| 37410928 | Medication-Wide Study: Exploring Medication Use 10 Years Before a Diagnosis of Inflammatory Bowel Disease. | Am J Gastroenterol | 2023 |
| 37279927 | Influence of Early Life Factors, including breast milk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease. | J Crohns Colitis | 2023 |
| 37308036 | Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study. | Clin Gastroenterol Hepatol | 2023 |
| 37274300 | Iron deficiency anemia impacts disease progression and healthcare resource consumption in patients with inflammatory bowel disease: a real-world evidence study. | Therap Adv Gastroenterol | 2023 |
| 37333091 | Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis. | bioRxiv | 2023 |
| 37266570 | A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn's Disease: A Population-based Study. | Inflamm Bowel Dis | 2023 |
| 37129981 | Selective IgA2 deficiency in a patient with small intestinal Crohn's disease. | J Clin Invest | 2023 |
| 37224198 | Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. | N Engl J Med | 2023 |
| 36753033 | Mild Crohn's Disease: Definition and Management. | Curr Gastroenterol Rep | 2023 |
| 36623926 | Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study. | Gut | 2023 |
| 36787834 | Preclinical Serological Signatures are Associated With Complicated Crohn's Disease Phenotype at Diagnosis. | Clin Gastroenterol Hepatol | 2023 |
| 36745039 | Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. | Inflamm Bowel Dis | 2023 |
| 36740199 | Reply. | Gastroenterology | 2023 |
| 36711839 | Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis. | bioRxiv | 2023 |
| 36640802 | Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data. | Clin Gastroenterol Hepatol | 2023 |
| 36464141 | Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. | Clin Gastroenterol Hepatol | 2023 |
| 36681073 | A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis. | Expert Rev Gastroenterol Hepatol | 2023 |
| 36634824 | Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis. | Gastroenterology | 2023 |